, Volume 25, Issue 5, pp 392–395 | Cite as

Immune abnormalities in diabetic patients not requiring insulin at diagnosis

  • U. Di Mario
  • W. J. Irvine
  • D. Q. Borsey
  • J. L. Kyner
  • J. Weston
  • C. Galfo


Islet cell antibodies (ICA), complement fixing islet cell antibodies, immune complexes and thyro-gastric autoantibodies were studied in newly diagnosed diabetic patients not requiring insulin at diagnosis. Particular attention was focussed on that minority of patients who are initially treated with diet or oral agents but show ICA in their serum. One hundred and six non-insulin-requiring patients were studied at clinical diagnosis. Seventeen who had ICA in their serum were compared with a control group of 89 who did not. The 17 ICA-positive diabetic patients were followed serologically for approximately 1 year from diagnosis. Patients were followed clinically for 3 years. Forty-seven percent of ICA-positive and 19% of ICA-negative patients had immune complexes in their serum. Eleven of the 17 ICA-positive patients also had serum complement fixing islet cell antibodies. Thyro-gastric antibodies were found in 29% of ICA-positive and 18% of ICA-negative diabetic patients. ICA, complement fixing antibody and immune complex positivity declined with time. Ten of the 17 ICA-positive and two of the 89 ICA-negative patients required insulin within 3 years of diagnosis. There was a positive trend for the presence of complement fixing islet cell antibodies at diagnosis to be associated with the early development of insulin dependency. The type of diabetes in ICA-positive patients not requiring insulin at diagnosis has strong immunological and clinical similarities to classical Type 1 (insulin-dependent) diabetes.

Key words

Type 1 diabetes Type 2 diabetes islet cell antibodies complement fixing islet cell antibodies immune complexes thyro-gastric autoantibodies 


  1. 1.
    Irvine WJ, Di Mario U, Guy K, Feek CM, Gray RS, Duncan LJP (1978) Immune complexes in newly diagnosed insulin dependent (Type 1) diabetics. J Clin Lab Immunol 1: 183–186Google Scholar
  2. 2.
    Fairchild RF, Kyner JL, Abbou NI (1982) Specific immunoregulation abnormality in insulin dependent diabetes mellitus. J Lab Clin Med 99: 175–186Google Scholar
  3. 3.
    Borsey DQ, Di Mario U, Irvine WJ, Gray RS, Weston J, Peutherer J, Duncan LJP (1983) Humoral immunity in Type 1 diabetes mellitus: a prospective study. J Clin Lab Immunol 11: 9–15Google Scholar
  4. 4.
    Mannik M, Haakenstad AO, Arend WP (1974) The fate and detection of circulating immune complexes. In: Brent L, Holborow J (eds) Progress in immunology II, vol 5. North Holland, Amsterdam, pp 91–101Google Scholar
  5. 5.
    National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039–1057Google Scholar
  6. 6.
    Hay FC, Nineham LJ, Roitt IM (1976) Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase Clq. Clin Exp Immunol 24: 396–400Google Scholar
  7. 7.
    Andreani D, Di Mario U, Ventriglia L, Galfo C, Iavicoli M (1982) Circulating immune complexes in diabetics with severe microangiopathy. Acta Endocrinol 99: 239–244Google Scholar
  8. 8.
    Bottazzo GF, Florin-Christensen A, Doniach D (1974) Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2: 1279–1282Google Scholar
  9. 9.
    MacCuish AC, Irvine WJ, Barnes EW, Duncan LJP (1974) Antibodies to pancreatic islet cells in insulin-dependent diabetics with coexistent autoimmune disease. Lancet 2: 1529–1531Google Scholar
  10. 10.
    Bottazzo GF, Dean BM, Gorsuch AN, Cudworth AG, Doniach D (1980) Complement fixing islet cell antibodies in Type 1 diabetes: possible monitors of active beta-cell damage. Lancet 1: 668–672Google Scholar
  11. 11.
    Irvine WJ, Di MarioU, Guy K, Borsey DQ (1980) Immune complexes in Type l diabetes with and without persistent islet cell antibody. J Clin Lab Immunol 4: 87–89Google Scholar
  12. 12.
    WHO Scientific Group Report (1977) The role of immune complexes in disease. WHO, Geneva, No. 6Google Scholar
  13. 13.
    Irvine WJ, McCallum CJ, Gray RS, Duncan LJP (1977) Clinical and pathogenic significance of pancreatic islet cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1: 1025–1027Google Scholar
  14. 14.
    Gorsuch AN, Lister J, Dean BM, Spencer KM, McNally JM, Bot-tazzoGF, Cudworth AG (1981) Evidence for a long prediabetic period in Type 1 (insulin dependent) diabetes mellitus. Lancet 2: 1363–1365Google Scholar
  15. 15.
    Betterle C, Caretto A, Tiengo A, Trevison A (1980) Complement fixing islet cell antibodies in Type 1 diabetes in susceptible patients with autoimmune diseases. Lancet 1: 1418–1419Google Scholar
  16. 16.
    Irvine WJ (1977) Classification of idiopathic diabetes. Lancet 1: 638–642Google Scholar

Copyright information

© Springer-Verlag GmbH & Co. KG 1983

Authors and Affiliations

  • U. Di Mario
    • 1
    • 3
  • W. J. Irvine
    • 2
  • D. Q. Borsey
    • 2
  • J. L. Kyner
    • 2
  • J. Weston
    • 2
  • C. Galfo
    • 1
  1. 1.Cattedra di EndocrinologiaUniversità La SapienzaRomeItaly
  2. 2.Endocrine Unit/Immunology Laboratories (Medicine) and Diabetic DepartmentRoyal InfirmaryEdinburghUK
  3. 3.Clinica Medica 2 Policlinico Umberto IRomaItaly

Personalised recommendations